All In MedTech

FDA Clearance Tracker · P180002-S005

Zephyr Endobronchial Valve (EBV) System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 30, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 30, 2019

Approved

Time to decision

225 days

Received Dec 17, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P180002-S005
Device name
Zephyr Endobronchial Valve (EBV) System
Applicant location
Redwood City, CA
Received
Dec 17, 2018
Decided
Jul 30, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P180002

Device type

Device class
Class III

Every decision under product code NJK

FDA's approval statement

As written in FDA's record.

Approval for the Zephyr 5.5-LP Endobronchial Valve (EBV) and the Zephyr 5.5 Dual Mark Endobronchial Delivery Catheter (EDC).

Source documents

Other decisions for Pulmonx Corporation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.